Statement Of Cash Flows [Abstract]

Ascelia Pharma - Filing #678716

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Interest paid, classified as operating activities
121,000 SEK
48,000 SEK
Interest received, classified as operating activities
1 314 SEK
635,000 SEK
Income taxes paid (refund), classified as operating activities
1 172 SEK
3 772 SEK
Cash flows from (used in) operating activities
126 792 SEK
125 263 SEK
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
- SEK
- SEK
Cash flows from (used in) investing activities
47,000 SEK
65,000 SEK
Cash flows from (used in) financing activities [abstract]
Payments of lease liabilities, classified as financing activities
906,000 SEK
1 016 SEK
Cash flows from (used in) financing activities
936,000 SEK
1 100 SEK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
127 682 SEK
126 428 SEK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
18,000 SEK
14 384 SEK
Cash and cash equivalents
21 855 SEK
149 555 SEK
261 599 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.